Shuzhen Tan

792 total citations · 1 hit paper
9 papers, 586 citations indexed

About

Shuzhen Tan is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shuzhen Tan has authored 9 papers receiving a total of 586 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shuzhen Tan's work include RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (4 papers) and Cancer-related gene regulation (2 papers). Shuzhen Tan is often cited by papers focused on RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (4 papers) and Cancer-related gene regulation (2 papers). Shuzhen Tan collaborates with scholars based in China. Shuzhen Tan's co-authors include Xiao Zhu, Dongpei Li, Xiangsheng Zhang, Kai Li, Guosheng Liang, Zhilin Zou, Yongmei Huang, Shu‐Guang Zhou, Jingzhong Liu and Yin Wu and has published in prestigious journals such as Biomedicine & Pharmacotherapy, BMJ Open and Frontiers in Oncology.

In The Last Decade

Shuzhen Tan

9 papers receiving 579 citations

Hit Papers

Cancer immunotherapy: Pros, cons and beyond 2020 2026 2022 2024 2020 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuzhen Tan China 6 250 239 182 138 107 9 586
Neha Papneja Canada 2 237 0.9× 370 1.5× 271 1.5× 129 0.9× 86 0.8× 4 723
Haozhe Huang China 13 253 1.0× 127 0.5× 166 0.9× 138 1.0× 98 0.9× 48 622
Zhiyan Zhu China 10 328 1.3× 196 0.8× 123 0.7× 122 0.9× 174 1.6× 11 592
Danfeng Luo China 17 328 1.3× 160 0.7× 106 0.6× 159 1.2× 95 0.9× 31 659
Alyssa Vito Canada 11 204 0.8× 210 0.9× 146 0.8× 95 0.7× 139 1.3× 18 555
Jingyao Tu China 13 182 0.7× 177 0.7× 142 0.8× 108 0.8× 70 0.7× 27 466
Roberto Ruiu Italy 15 284 1.1× 194 0.8× 178 1.0× 65 0.5× 114 1.1× 18 600
Shengbin Shi China 12 261 1.0× 120 0.5× 202 1.1× 139 1.0× 114 1.1× 24 518
Yuan‐Tong Liu China 14 319 1.3× 384 1.6× 365 2.0× 193 1.4× 136 1.3× 18 894

Countries citing papers authored by Shuzhen Tan

Since Specialization
Citations

This map shows the geographic impact of Shuzhen Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuzhen Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuzhen Tan more than expected).

Fields of papers citing papers by Shuzhen Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuzhen Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuzhen Tan. The network helps show where Shuzhen Tan may publish in the future.

Co-authorship network of co-authors of Shuzhen Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Shuzhen Tan. A scholar is included among the top collaborators of Shuzhen Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuzhen Tan. Shuzhen Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Xu, Yue, Tao Tao, Shi Li, et al.. (2022). Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma. Frontiers in Genetics. 13. 975905–975905. 9 indexed citations
3.
Zou, Zhilin, Shu‐Guang Zhou, Guosheng Liang, et al.. (2021). The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators. Molecular Omics. 17(3). 438–453. 21 indexed citations
4.
Zou, Zhilin, Shu‐Guang Zhou, Guosheng Liang, et al.. (2021). Correction: The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators. Molecular Omics. 17(4). 641–641. 1 indexed citations
5.
Tan, Shuzhen, Zesong Li, Kwok Yan Li, et al.. (2021). The Regulators Associated With N6-Methyladenosine in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Reveal New Clinical and Prognostic Markers. Frontiers in Cell and Developmental Biology. 9. 741521–741521. 8 indexed citations
6.
Zhang, Xiangsheng, Zhilin Zou, Guosheng Liang, et al.. (2021). Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases. Frontiers in Oncology. 11. 623170–623170. 25 indexed citations
7.
Tan, Shuzhen, Dongpei Li, & Xiao Zhu. (2020). Cancer immunotherapy: Pros, cons and beyond. Biomedicine & Pharmacotherapy. 124. 109821–109821. 501 indexed citations breakdown →
8.
Wu, Yin, et al.. (2002). Methylation of p16 and p15 genes in multiple myeloma.. PubMed. 17(2). 101–5. 15 indexed citations
9.
Tan, Shuzhen, et al.. (1999). Inactivation of p16 gene in leukemia.. PubMed. 14(4). 206–10. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026